5,5-dichloro-4-hydroxy-pentan-2-one | 38666-07-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5,5-dichloro-4-hydroxy-pentan-2-one
• 英文别名: 5,5-Dichloro-4-hydroxypentan-2-one
• CAS: 38666-07-8
• 化学式: C₅H₈Cl₂O₂
• 分子量: 171.023
• InChiKey: NRXVBKUKVBXCAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,5-dichloro-4-hydroxy-pentan-2-one 在 sodium hydroxide 作用下， 生成 2,4-戊二烯酸
  参考文献：
  名称：

  Allylic rearrangement. III. Favorskii-type rearrangemnt of the vinylogs of .alpha.-chloroacetones

  摘要：

  DOI：

  10.1021/jo00949a020
• 作为产物：
  描述：

  二氯乙醛 、 乙酰乙酸乙酯 生成 5,5-dichloro-4-hydroxy-pentan-2-one
  参考文献：
  名称：

  Allylic rearrangement. III. Favorskii-type rearrangemnt of the vinylogs of .alpha.-chloroacetones

  摘要：

  DOI：

  10.1021/jo00949a020

文献信息

• [EN] N-METHYL AMINO ACIDS<br/>[FR] ACIDES N-METHYL AMINES
  申请人：UBIQUITOUS TECHNOLOGIES PTY LT

  公开号：WO2004007427A1

  公开（公告）日：2004-01-22

  The present invention relates to a compound of formula (I) or (II), processes for preparing them, peptides including them and kits involving them.

  这项发明涉及到式(I)或(II)的化合物，制备它们的方法，包括它们的肽和涉及它们的试剂盒。
• Alkylacylimidazoles in Claisen–Schmidt and Knoevenagel Condensations
  作者：H. Quan、L. Wang、Zh. Wang、X. Mei、J. Ning、D. She

  DOI：10.1134/s1070428020080187

  日期：2020.8

  Claisen–Schmidt condensation of N-acetylimidazole with benzaldehyde followed by acidification with HCl gave cinnamic acid. The Knoevenagel-like condensation of N-(acetoacetyl)imidazole with hydrated aldehydes resulted in a fast and efficient formation of β-hydroxyketones. The studied reactions provide a new and general synthetic approach to cinnamic acid derivatives and β-hydroxyketones, as well as a

  摘要 烷基酰基咪唑已被证明是克莱森-施密特和克诺韦尼格尔式缩合反应的良好试剂。N-乙酰基咪唑与苯甲醛的Claisen-Schmidt缩合，然后用HCl酸化，得到肉桂酸。N-（乙酰乙酰基）咪唑与水合醛的Knoevenagel样缩合导致快速有效地形成β-羟基酮。所研究的反应为肉桂酸衍生物和β-羟基酮的合成提供了一种新的通用方法，以及烷基酰基咪唑的新应用领域。
• [EN] SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY<br/>[FR] PYRIDAZINES SUBSTITUEES ET PYRIDAZINES FUSIONNEES POSSEDANT UNE ACTIVITE D'NHIBITION DE L'ANGIOGENESE
  申请人：BAYER AG

  公开号：WO2001010859A1

  公开（公告）日：2001-02-15

  Substituted and fused pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R?1 and R2¿ may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

  具有抑制血管生成活性的取代和融合吡啶并噻唑化合物，其具有广义结构式（I），其中包含A，B，D，E和L的环是含氮杂环；X和Y基团可以是各种定义的连接单元之一；R?1和R2¿可以是定义独立的取代基，或者一起可以是定义环的桥；环J可以是芳香族，吡啶基或环烷基团；G基团可以是各种定义的取代基。还公开了含有这些材料的制药组合物以及使用这些材料治疗具有异常血管生成或高渗透性过程的哺乳动物的方法。
• Quinazoline derivatives and pharmaceutical compositions containing them
  申请人：Thomas Peter Andrew

  公开号：US20050239777A1

  公开（公告）日：2005-10-27

  The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R 1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, or —NR 5 R 6 (wherein R 5 and R 6 , which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X 1 represents —O—, —CH 2 —, —S—, —SO—, —SO 2 —, —NR 7 CO—, —CONR 8 —, —SO 2 NR 9 —, —NR 10 SO 2 — or —NR 11 — (wherein R 7 , R 8 , R 9 , R 10 and R 11 each independently represents hydrogen, C 1-3 alkyl or C 1-3 alkoxyC 2-3 alkyl); R 4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及公式（1）的喹唑啉衍生物，其中m为1到2的整数；R1代表氢、羟基、卤素、硝基、三氟甲基、氰基、C1-3烷基、C1-3烷氧基、C1-3烷硫基或-NR5R6（其中R5和R6可以相同或不同，每个代表氢或C1-3烷基）；R2代表氢、羟基、卤素、甲氧基、氨基或硝基；R3代表羟基、卤素、C1-3烷基、C1-3烷氧基、C1-3酰氧基、三氟甲基、氰基、氨基或硝基；X1代表-O-、-CH2-、-S-、-SO-、-SO2-、-NR7CO-、-CONR8-、-SO2NR9-、-NR10SO2-或-NR11-（其中R7、R8、R9、R10和R11各自独立地代表氢、C1-3烷基或C1-3烷氧基C2-3烷基）；R4代表可选取代的5或6成员饱和碳环或杂环基或烯基、炔基或可选取代的烷基，其中烷基基团可以包含一个杂原子连接基团，烯基、炔基或烷基基团可以携带一个末端可选取代的基团，所选的基团为烷基或5或6成员饱和碳环或杂环基，以及其盐；制备它们的方法，含有公式（I）化合物或其药学上可接受的盐作为活性成分的制药组合物。公式（I）化合物及其药学上可接受的盐抑制VEGF的作用，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值的特性。
• N-methyl amino acids
  申请人：Aurelio Luigi

  公开号：US20050245432A1

  公开（公告）日：2005-11-03

  The present invention relates to a compound of formula (I) or (II), processes for preparing them, peptides including them and kits involving them.

  本发明涉及公式(I)或(II)化合物，制备它们的方法，包括它们的肽和涉及它们的试剂盒。